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Abstract 
We demonstrate the first use of the nullomer (absent sequences) approach to drug discovery and development. 
Nullomers are the shortest absent sequences determined in a species, or group of species. By identifying the 
shortest absent peptide sequences from the NCBI databases, we screened several potential anti-cancer peptides. 
In order to improve cell penetration and solubility we added short poly arginine tails (5Rs), and initially 
solubilized the peptides in1M trehalose. The results for one of the absent sequences 9R (RRRRRNWMWC), 
and its scrambled version 9S1R (RRRRRWCMNW) are reported here. We refer to these peptides derived from 
nullomers as PolyArgNulloPs. A control PolyArgNulloP, 124R (RRRRRWFMHW), was also included. The 
lethal effects of 9R and 9S1R are mediated by mitochondrial impairment as demonstrated by increased ROS 
production, ATP depletion, cell growth inhibition, and ultimately cell death. These effects increase over time 
for cancer cells with a concomitant drop in IC-50 for breast and prostate cancer cells. This is in sharp contrast to 
the effects in normal cells, which show a decreased sensitivity to the NulloPs over time. 
 
1. Introduction 
This study investigates the biological properties of the smallest absent peptides, nullomer peptides 
(NulloPs). These peptides were identified after a search of the NCBI databases, which counted all occurrences 
of peptide strings, and generated a list of the smallest peptide sequences (currently length-5 amino acids) absent 
from natural databases. While combinatorial and phage display libraries have been used to generate peptide 
drugs that were not derived from nature, we have taken a completely new approach to look for effective cancer 
drugs; we look specifically for what does not exist [21]  in nature. Acquisti et al. have dismissed this approach 
[1], claiming that absent sequences are actually a consequence of mutation and will not be useful for medical or 
labeling purposes; but others have explored the distribution of absent sequences suggesting possible 
applications [7,31,42]. We have used a new algorithm for this negative in-silico selection that enables us to 
identify small epitopes with possible lethal effects [21]. While others have debated whether this approach might 
yield lethal sequences [5,42], we have now shown that several of these peptides are in fact lethal at micromolar 
concentrations. Our approach originally generated hundreds of NulloPs (unpublished data), and we have been 
characterizing their biological effects, seeking to exploit their killing mechanisms to ultimately produce new 
anticancer peptides. This report focuses on NulloP 9 (NWMWC), its scrambled version 9S1 (WCMNW); and 
NulloP 124 (WFMHW). To ensure cell penetration we conjugated the NulloPs with PolyArg (RRRRR). 
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Cancer therapy is a combination of surgery, chemotherapy, radiotherapy and recently growth factors and 
cytokines, and has not yet met our dreams of curing this disease [2]. In spite of the application of a wide variety 
of drugs, anti cancer chemotherapy has always been limited by side effects and chemoresistance [41]. The 
extreme genetic adaptability of cancer cells in their ultimate quest of immortality and independence  gives these 
cells several survival advantages in harsh conditions; for example they can stop cell division and enter a state of 
dormancy, or become stem cells capable of regenerating the original tumor [27]. 
Cancer cells are resistant to apoptosis induction, and a new paradigm in cancer therapy is emerging. Cancer 
cells survive because their metabolism is altered with significant changes in mitochondrial function, and a lower 
dependence on pyruvate oxidation, the Warburg effect [6]. The therapeutic approach known as mitochondrial 
medicine [11,12,16] is justified for several reasons: cancer mitochondria have low oxidative phosphorylation, 
high Δψm and reactive oxygen species (ROS) output, and a deregulated apoptotic pathway [12]. The 
mitochondrial outer membrane permeabilization (MOMP) constitutes a “point of no return,” in that once it 
begins, cells are destined to die by apoptosis or necrosis [29]. Chemicals targeting the mitochondria have the 
advantage to initiate the MOMP independently of upstream signals that are frequently impaired in cancer cells, 
and thus bypass chemoresistance [12,16]. 
Already many chemicals and peptides (derived from existing proteins involved in cell death) that target the 
intrinsic mitochondrial death machinery are being used in clinical trials [12,16]. Other natural peptides such as 
defensins [10,39,53] (endogenous antimicrobial peptides produced by leukocytes and epithelial cells), have 
demonstrated anticancer potential. Their mechanism of action involves a stimulation of the immune system 
[10,56], but it is still not clear what makes cancer cells susceptible to these peptides. The general mechanisms 
suggested are: lysis of cancer cells [49,23], plasma membrane disruption via micellization or pore formation 
[50], and induction of apoptosis via mitochondrial membrane disruption [48]. 
One of the characteristics of the NulloPs described here is their high hydrophobicity due to the presence of 
TRP and MET. Their poor solubility in water becomes a major obstacle for their use. In order to overcome this, 
we fused them to a cell penetrating peptide (CPP). This is a well established approach that started with the 
observation that the human immunodeficiency virus 1 (HIV-1) Tat protein can enter cells efficiently in vitro 
[13]. In 1997, Vives et al. [51] discovered that an 11 amino acids sequence, Tat 48-60 (GRKKRRQRRRPPQ) 
known as the Tat peptide, can enter cells more efficiently than the full length Tat protein. A PolyArg peptide 
made from 6 to 9 L-ARG maintains the same cell penetrating capacity as the original Tat peptide [52]. The 
mechanism(s) of internalization of PolyArg CPP is still a controversial matter. There are two principal routes of 
internalization: endocytosis (an energy dependent process), and transduction through cellular membrane.  
PolyArg CPP [45] and Tat protein [36] interact with the cell membrane by inducing a Gaussian membrane 
curvature as a prelude to pore formation through which transduction to the cytosol occurs. In spite of the pore 
formation, after transduction of PolyArg CPP and its cargo inside the cell, the cell membrane integrity is not 
compromised and the cell remains negative for propidium iodide (PI) staining [37]. The release of the cargo 
from the PolyArgCPP-Cargo complex has not yet been demonstrated [34]. 
We have proposed that by identifying the smallest absent DNA sequences, we can find short peptides 
eliminated by natural selection. These sequences may have unusual properties that can be exploited for drug 
development [21]. This report demonstrates the anticancer benefits of the nullomer approach, and shows that 
NulloPs can affect the growth of several cancer cell lines by mitochondrial impairment.  
2. Methods 
2.1 Cell culture 
Cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas, 
VA). The human and murine cancer lines are: LnCap (CRL-1740) derived from a human prostate carcinoma, 
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MDA-MB-231 (HTB-26) derived from a human breast adenocarcinoma, B16 (CRL-6322) derived from a 
C57BL/6J mouse skin melanoma, HUT102 (TIB-162) derived from an ATL (HTLV-1 Adult T cell Leukemia)  
a gift from Dr. T.A. Waldmann (NIH/NCI ), J774A.1 (TIB-67) mouse monocyte/macrophage derived from a 
BALB/cN reticulum cell sarcoma. Primary normal cell lines were used as well: PCS (PCS-440-010) normal 
primary prostate epithelial cells, HMEC (ECACC-HMEC 830-05a) normal human mammary cells, WI-38 
(CCL-75) human embryonic fibroblasts derived from a 3 months  gestation fetus. LnCap, MDA-MB-231, and 
HUT102 were cultured in RPMI 1640 supplemented with 10% Hyclone Fetal Bovine Serum (FBS) and 1X 
Penicillin Streptomycin (100X solution, Invitrogen). B16 and WI-38 were cultured in DMEM supplemented 
with 10% Hyclone FBS and 1X Penicillin Streptomycin. PCS cells were cultured in the Prostate Epithelial Cell 
Basal Medium (PCS-440-030) supplemented with the Prostate Epithelial Cell Growth Kit (PCS-440-040). 
HMEC cells were cultured in the Clonetics MEGM BulletKit (CC-3150). Cell cultures were incubated at 37ºC 
and 5% CO2. For PCS and HMEC cells we used passages 2-4. The passaging of cells was done at 80% 
confluence; after a PBS wash, cells were treated with Trypsin-EDTA 0.25% (Invitrogen). Cells were seeded in 
96 well plates (Costar) and allowed to adhere to the surface overnight, then the old media was removed and 
replaced with 90 µl fresh media, with 10 µl containing peptides or other treatment. 
2.2 Cell viability assay 
Cell viability was measured by the colorimetric MTT assay (Sigma, St Louis MO). 3000-5000 cells/well 
were seeded in 96 well plates and exposed to peptides or other treatments. At each time point, the MTT solution 
(5 mg/ml in PBS) was added directly to wells and incubated at 37°C for 4 h, then the formazan crystals  
solubilized with 100 µl dimethyl sulfoxide (DMSO), and incubated for 1h at 37ºC. Absorbance at 570 nm was 
taken by a plate reader (SynergyMx from Biotek, Winooski VT). Plate readings were exported to Microsoft 
Excel and GraphPadPrism software. All the wells were analyzed in triplicates. The statistical analysis was done 
with the GraphPadPRISM*. 
2.3 PolyArg-peptides synthesis 
The PolyArgNulloPs were made by Elim Biopharmacuticals (Hayward, CA) and Pierce Biotechnology 
(Rockford, IL). HPLC purified peptides (purity >98%) were delivered in 1 to 2 mg/tube (lyophilized) format 
and stored at -20°C. Peptides were solubilized in 1M trehalose to produce 100 mM stock solutions. Only freshly 
prepared solutions were used to treat cells. Several concentrations of the peptides were used with a range from 
5-10 µM to 100 µM. The trehalose concentration in all reactions was 1 mM (a dose without any effect on cell 
growth). 
2.4 Preparation for scanning electron microscopy 
Cells were cultured as described above in 35 mm dishes containing cover slips. Cover slips were prefixed in 
4% paraformaldehyde in PBS for 30 minutes (mn), washed in distilled water 3 times for 5 mn each and placed 
in 2.5% glutaraldehyde for 30 mn, followed by washing in distilled water as described. Cover slips were then 
placed in 0.5% osmium tetroxide for 30 mn and washed again in distilled water. Cover slips were then 
transferred to 1% tannic acid for 30 minutes, washed in distilled water and transferred a second time to 0.5% 
osmium tetroxide, and washed again in distilled water. Cover slips were dehydrated in ethanol (30%, 50%, 
70%, 80%, 90% and 100% × 3), 5 mn each. The cover slips were transferred to a K850 critical point dryer 
(Quorum Technologies, Ashford, UK) using 100% ethanol as the transitional fluid. Dried cover slips were 
sputtered with gold (~20 nm) in a CrC150 sputter coater (Torr International, New Windsor, NY, USA), and 
examined in a Hitachi S-3400N scanning electron microscope. 
2.5 HCS Mitochondrial Health Assay 
The HCS Mitochondrial Health Kit (Invitrogen, Carlsbad CA) uses two dyes: the MitoHealth stain  
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(excitation/emission maxima 550/580 nm) accumulates in the mitochondria of live cells proportional to the 
mitochondrial membrane potential, Hoechst 33342 (excitation/emission 350/461 nm) stains nuclear DNA in 
live and dead cells. Cells were seeded in 96 well plates and incubated with peptides for 24h. Then 50 µl of 
MitoHealth stain was added to each well and incubated for 30 mn. After removing the media, Hoechst 33342 
and 3.7% paraformaldehyde were added to cells. After washing the cells  twice with  PBS,  colorimetric reading 
was taken with the plate reader. Relative fluorescence was measured in BioTek Synergy plate reader. This kit 
was manufactured for imaging, but we standardized it with SynergyMx plate reader for reading 96-well plates. 
2.6 Measurement of total cellular ATP content  
 Cells were seeded in 96 well plates (white plates from Nunc to block luminescence bleeding between the 
wells) and allowed to attach for 24h. Then cells were incubated for 2h, 24h and 48h with peptides (1-50 µM of 
9R, 9S1R and 124R), or 100mM sodium azide as an ATP depletion control [26] At each time point a single 
reagent, Cell Titer GlowTM (Promega), was added to cells.. Complete reagent mixing in 96 wells plates required 
gentle orbital shaking for 2-10 mn. The plate reading was taken by SynergyMx plate reader. Plate readings were 
exported to Microsoft Excel and GraphPadPrism software. All the wells were analyzed in triplicates. The 
statistical analysis was done with the GraphPadPRISM*. 
2.7 Live/Dead assay  
Each peptide’s effect on cell vitality was measured by the live/dead assay kit from Invitrogen (Carlsbad, 
CA). This kit uses Hoechst 33342 as a nucleic acid stain (blue fluorescence) and PI (red fluorescence). Since PI 
is not permeant to live cells, it is commonly used to detect dead cells in a population. The PI concentration used 
in this study was 6.25µg/ml. After 2h incubation with PolyArgNulloPs, cells were stained directly in the 
reaction media with these two stains, and fluorescent images were taken by Zeiss axiovert 40 microscope 
(Oberkochen, Germany) using a SPOT imaging camera (Sterling Heights, MI). 
2.8 Super Oxide Assay 
After 24h incubation in 96 wells microplates, cells were treated with peptides or control for 2h. Then 
MitoSOX™ red reagent (Invitrogen) was added for 10 mn, and washed with PBS. The final plate reading was 
taken in SnyergyMX plate reader.  
2.9 Hemolytic activity 
    The hemolytic activity of PolyArgNulloPs was determined on human red blood cells (RBCs) from healthy 
volunteers. Blood samples were centrifuged and RBCs washed twice with PBS. A 10% RBCs suspension was 
incubated with 10 µM, 25 µM and 100 µM of peptides (9R, 9S1R and 124R) at 37°C for 24 h with 100 rpm 
shaking. PBS was used as a negative control (0% lysis: AControl), and 1% Triton X-100 as a positive control 
(100% lysis: ATotal). After incubation the samples were centrifuged and supernatants transferred into a 96-well 
plate to quantify RBCs lysis by a spectrophotometric reading at λ=405 nm [23]. The hemolytic activity [20] in 
% was calculated using this formula: Hemolytic activity in %={[ASample-AControl]/[ATotal-AControl]}x100 
2.10 Statistical analysis 
All results are expressed as mean ± SE (standard error). The statistical analysis was done with the 
GraphPadPRISM* version 5.03 using one-way analysis of variance (ANOVA) followed by a Tukey’s post test. 
A p-value of less than 0.05 was considered statistically significant.  
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3. Results 
3.1 The in vitro effect of PolyArgNulloPs peptides on cell growth 
Cells were exposed to different doses (10-100 µM) of PolyArgNulloPs (9R, 9S1R and 124R) for 2h, 24h 
and 48h. For each time period, the exposure of cells to the peptides was continuous with no change of the 
culture medium. The 2h time point was aimed at detecting toxic effects similar those of the control treatment 
H2O2 (0.01%). The 24h and 48h time points were used to examine peptide effects related to the cell cycle.  
The results show clearly that peptide 124R has no effect on the growth of LnCap prostate cancer 
(Suppl.R1A) or MDA-MB-231 (Suppl.R1B) cells. Peptide 124R is a PolyArgNulloP with the same number of 
amino acids, and the same poly Arginine content as 9R, 9S1R, and can be considered a control peptide. The 
peptide 9R at 100 µM has a toxic effect at 2h on LnCap cells, similar to the effect of H2O2 (0.01%). At 24h and 
48h, 9R has a moderate effect on LnCap at 20-30 µM, and an almost completely lethal effect at 50-100 µM. 
However, we do not observe a classic dose dependent effect between 5-100 µM with 9R in LnCap cells. With 
the MDA-MB-231 cells, peptide 9R produces a dose dependent effect (10-100 µM) at 2h, 24h and 48h. The 
peptide 9S1R shows a dose dependent effect over 10-100 µM at 2h for both the LnCap (Suppl.R1A), and 
MDA-MB-231 (Suppl.R1B) cells. This toxic effect is also seen at 24h and 48h.  
The melanoma B16 cell line was included in this study because skin melanoma is the sixth most prevalent 
cancer in North America, and its incidence is on the rise [14]. The three peptides 9R, 9S1R and 124R at doses 
10-100 µM, and at time points from 2h to 96 h (Suppl.R1C), have no effect on the growth of B16 cells. 
Peptide 124R, at doses 10-100 µM, at time points from 2h to 96h, has no effect on the growth of HUT 102 
cells. However, peptide 9R and 9S1R have a toxic effect at 100 µM seen from 2h. In addition, a dose response 
was observed from 10-100 µM at time points from 48h to 72h. In highest range of doses (50-100 µM), a dose 
dependent effect is only observed at the 96h time point (Suppl.R1D). 
The peptides 9R, 9S1R and 124R have no effect on the growth of J774A.1 cells at doses 10-100 µM, from 
2h to 72h. At 96h, peptide 124R has no effect; but there is a dose dependent effect with 9R and 9S1R (although 
the effect is more pronounced with 9R) (Suppl.R1E). Microscopically, the cells swell and contain many 
vacuoles (data not shown).  
We also examined the effects of the peptides 9R, 9S1R and 124R on normal cells. Peptide 124R has no 
effect on the growth of WI-38 (Suppl.R1F), and PCS (Suppl.R1G) cells up to 48h time point (10-100 µM). 
However at the highest concentration (100 µM) peptide 124R has an effect on the growth of HMEC cells 
(Suppl.R1H) at 24h, and to a lesser extent at 48h. Peptide 9R and 9S1R have a moderate dose dependent effect 
(20-100 µM) on WI-38 cells at 24h, and that effect is restricted to the 50-100 µM treatments at 48h 
(Suppl.R1F). Peptide 9R and 9S1R have a moderate effect on the growth of PCS cells at 24h and 48h time 
points (Suppl.R1G). In addition, peptides 9R and 9S1R have a dose dependent effect (10-100 µM) on the 
growth of HMEC cells at the 24h and 48h time points (Suppl.R1H). 
Scanning electron micrographs of LnCap and MDA-MB-231 cells treated with 9R (Fig. 1E, F, respectively) 
and 9S1 (Fig 1G, H, respectively) for 48 hours (100 µM), show greatly reduced cell density compared to 
untreated LnCap (Fig. 1A) and MDA-MB-231 (Fig. 1B) cultures. Cells treated with the control peptide 124R 
(Fig 1C, c, D, d) appear similar to untreated cells (Fig. 1A, a, B, b). At higher magnification the morphology of 
9R and 9S1 treated cells show substantial membrane damage including blebbing and tearing (Fig. 1e, f, g, h). 
3.2 The IC-50 evolution of PolyArgNulloPs peptides in vitro 
We calculated the IC-50 of peptides 9R, 9S1R and 124R at every time point where there is an effect on the 
growth of cells. As shown in Table 1, the evolution of IC-50 for cancer cells is different from that seen in 
normal cells. For LnCap cells, the 9R IC-50 starts high at the 2h time point (44±2.5 µM), and drops by 48h 
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(28±1.6 µM). The same pattern of IC-50 evolution for 9R is seen in MDA-MB-231 cells, where the IC-50 is 39 
±1.8 µM at 2h, and falls to 16±0.9 µM at the 48h time point. The same pattern can be seen with peptide 9S1R; 
for LnCap cells the IC-50 starts at 26±1.3 µM at 2h and falls to less than 8±0.5 µM at the 48h time point. For 
MDA-MB-231 cells, with 9S1R the IC-50 starts at 18±0.5 µM at the 2h time point, and drops to 10±0.3 µM at 
the 48h time point. For HUT102 cells, the IC-50 for 9R starts at 93±2.3 µM at the 2h time point, and falls to 
25±1.6 µM at 96h time point. This observation shows clearly that the cancer cells are more sensitive to 9R and 
9S1R over time. Normal cells show an opposite pattern. For PCS and HMEC cells, the IC-50 for 9R, 9S1R and 
even 124R rises with time. This means that the sensitivity of normal cells to 9R, 9S1R and 124R diminishes 
with time, while the sensitivity of the cancer cells increases with time. The obvious potential clinical importance 
of this finding needs to be validated in animal models.  
3.3 PolyArgNulloPs effects on cellular ATP level  
 
   We studied the effects of peptides 9R, 9S1R and 124R on total cellular ATP content in LnCap and MDA-MB-
231 cells. Peptide 124R at doses 1-50 µM, for time points from 2h to 48h, has no effect on the cellular level of 
ATP in LnCap and MDA-MB-231 cells (Fig. 2). This is consistent with the observation that peptide 124R does 
not affect cell growth. Peptide 9R has a moderate effect at the 2h time point with 50 µM peptide in both cell 
lines. This effect persists at the 24h time point. By 48h, there is a 50% and 65% reduction with 25 µM and 50 
µM 9R (respectively), this latter effect is similar to that seen with our control 100 mM sodium azide. Peptide 
9S1R at 50 µM almost completely shuts down ATP production in both cell lines (LnCap and MDA-MB-231) 
by the 2h time point, an effect more drastic than the sodium azide control. This is a toxic effect similar to that of 
anthrax toxin in J774A.1 cells [3,4]. In addition, at 25 µM peptide 9S1R reduces the ATP level by 50% at the 
2h and 24h time points, and by 85% at the 48h time point. The effect is even more dramatic in LnCap cells, 
where 9S1R at 48h produces a 50% reduction of ATP level at 5-10 µM.  
3.4 PolyArgNulloPs effects on mitochondrial function 
Mitochondrial Membrane Potential (MMP) is the driving force behind ATP production by the mitochondrial 
respiratory chain. As shown in (Fig. 3a) and (Fig. 3b), peptide 124R has no effect on MMP at 24h in either the 
LnCap or MDA-MB-231 cell lines. Peptide 9R at 50-100 µM reduces by 40% the MMP in both cell lines. 
Peptide 9S1R has dramatic effects on MMP, producing a 40% reduction at 30-100 µM in LnCap cells. In 
MDA-MB-231 the reduction of MMP is even more dramatic: 40% reduction at 20-30 µM, and 95% reduction 
at 50-100 µM.  
Superoxide free radicals production is indicative of mitochondrial damage. We investigated the ROS 
production 2h after exposure to the PolyArgNulloPs, before any cellular mechanisms can scavenge these free 
radicals. As shown in (Fig. 4a) and (Fig. 4b), for both LnCap and MDA-MB-231, peptide 124R at 10-100 µM 
has no effect on the production of ROS. However, for both cell lines, peptide 9R at 50-100 µM produces more 
free radicals than the control H2O2 (0.01%). Peptide 9S1 at 10-100 µM induces ROS production in a dose 
dependent manner in LnCap cells, and produces a dramatic increase of ROS production at 100 µM in MDA-
MB-231 cells. It is noteworthy that 9R and 9S1R at 100 µM in both cell lines induces more ROS production 
than the H2O2  (0.01%) treated cells. 
3.5 Effects of PolyArgNulloPs on RBCs 
   It is well known that some peptides puncture the cell membrane of RBCs, and this side effect can limit their 
therapeutic potential. We exposed the PolyArgNulloPs (10µM, 25µM and 100 µM) to human RBCs from 
healthy donors for 24h at 37ºC. As shown in (Fig. 5), peptides 9R and 124R have no hemolytic effect on human 
RBCs, and peptide 124R produces only 1% hemolysis at 100 µM. In contrast, peptide 9S1R has significant 
hemolytic activity: 0.5% at 10 µM, 2.5% at 25µM, and 12% at 100 µM. The hemolytic activity of peptide 9S1R 
may explain its rapid toxic effects at 2h. 
7	  
3.6 Live/Dead Assay 
   We performed this analysis at the 2h time point, and used PI as a marker of cell death. Only cells with 
compromised membrane integrity become PI positive. As shown in (Suppl.R2A) and (Suppl.R2B), both cell 
lines (LnCap and MDA-MB-231) exposed to H2O2 (0.01%) for 2h are nearly 100% PI positive. The untreated 
cells are all PI negative. Cells treated with 100 µM of peptide 124R for 2h show few PI positive cells (less than 
1%). Both cell lines exposed to peptide 9R at 10 µM or 50 µM for 2h show no effect on PI entry. At 100 µM 
9R, both cell lines show significant cell death (30-40% become PI positive). 9S1R has stronger effects on both 
cell lines, as 30-40% become PI positive with 50 µM 9S1R, and almost 100% are PI positive at 100 µM 9S1R. 
This result is consistent with the effects of 100 µM 9S1R (2h time point) on cellular ATP and cell survival. But 
the 2h time point is too short for an apoptotic process, and the drop in ATP level also contradicts and apoptotic 
model of cell death. This response is also not typical of necrosis, since cell swelling is not observed.  
4. Discussion 
4.1 Solubilization of PolyArg peptides in trehalose 
The original Nullomer peptides 9 (NWMWC), 9S1 (WCMNW) and 124 (WFMHW) are composed of two 
types of amino acids: MWF (hydrophobic non polar), and CNH (polar but uncharged). They are insoluble in 
water, and though they are initially soluble in absolute ethanol, after mixing with culture medium they 
precipitate. We solubilized the PolyArg conjugated peptides in 1M trehalose (though the NulloPs without 
PolyArg are insoluble in 1M trehalose). The solubilization process was instantaneous, and PolyArg conjugated 
peptides remain stable in solution at room temperature. Trehalose has a water replacing capacity and most likely 
surrounds the hydrophobic peptides with a carbohydrate coat [30]. It has been used extensively in the 
formulation of therapeutic proteins, because of its qualities as a protein-stabilizer [25]. This is the first time to 
our knowledge that a CPP conjugated cargo has been solubilized in trehalose. While others [52] report that an 
R5 tail is not sufficient for cell penetration, the conjugation of an R5 tail to our peptides 9, 9S1 and 124, 
facilitates solublization in trehalose.  
4.2 PolyArgNulloPs potential for cancer treatment  
The treatment of human cancer is not a single drug therapy. A cocktail of drugs aimed at different targets in 
cancer cells is used to avoid drug resistance. Potential drugs against cancer are characterized by their IC-50, 
which is the dose that inhibits the growth of 50% of the cell population exposed to the drug. Protocols have 
been established in the USA by the NCI/NIH [9,40], and in Japan [55], for testing potential new drugs against a 
panel of cell lines. The current protocols expose cancer cells to drugs for 48h [57] or 72h [40], followed by cell 
viability assays. It is noteworthy that the screening systems available like the NCI-60 panel of cancer cells 
[9,40], the JFCR39 panel of 39 cell lines used in Japan [55] or the recently established CMT1000 (Center for 
Molecular Therapeutics 1000) panel consisting of 1200 cancer cell lines [46], do not include normal cells as 
controls. The differential sensitivity of cancer cells and normal cells, to cancer drugs, is a complex area. In some 
studies, normal cells are not sensitive at all to cancer drugs [38]. In other studies, the response of normal cells to 
cancer drugs depends on the culture protocol: contact inhibited quiescent 3T3 fibroblasts are not sensitive (to 
cisplatin and etoposide) [24], while exponentially dividing 3T3 fibroblasts [24] and MCF-10A (normal human 
mammary epithelial cell line) are sensitive [8]. 
The results presented here include an analysis of the PolyArgNulloPs differential IC-50 evolution in normal 
and cancer cells. LnCap and MDA-MB-231 cells were included in our study because they represent, 
respectively, the most frequent cancer in men (prostate cancer) and women (breast cancer). We looked at the 
killing potential of PolyArgNulloPs at 3 different time points to assess their cytotoxicity and effect on growth. 
As shown in Table 1, the IC-50 evolution of 9R and 9S1R in LnCap and MDA-MB-231 demonstrates that these 
cancer lines have an increasing sensitivity to our peptides over time, while the normal cell lines have a 
decreasing sensitivity. The LnCap IC-50 of 9R starts at 44 ±2.5 µM at 2h, and falls to 28 ±1.6 µM by 48h. The 
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LnCap IC-50 for 9S1R starts 26 ±1.3 µM at 2h, and drops to 8 ±0.5 µM at 48h. The same pattern is seen with 
MDA-MB-231 cells, HUT102 cells and J774A.1 cells. For normal cells like PCS and HMEC, the opposite 
pattern is seen. The PCS IC-50 of 9R starts at 28 ±1.1 µM at 2h, and reaches 35±1.3 µM at 48h. For HMEC 
cells, the IC-50 for 9R starts at 20 ±0.8 µM at 2h, and reaches 34 ±1.2 µM at 48h. This differential pattern of 
the IC-50 evolution for our peptides shows clearly that normal cells, although inhibited by our peptides can 
recover, while the sensitivity of cancer cells increases with time. Other researchers have found similar patterns 
of increased sensitivity for taxol and other drugs [18,32,33,35,44]. Unfortunately, these early observations were 
not investigated further, and these studies failed to include normal cells [18,32,33,35,44]. The parallel 
evaluation of cancer cells and normal cells in regard to their sensitivity to cancer drugs is important, because the 
side effects of cancer drugs on normal cells are a major clinical issue. To our knowledge the differential 
evolution of IC-50 in cancer cells versus normal cells is assessed for the first time here. This comparison of 
normal versus cancer cell sensitivity over time, may be useful to future screening efforts. 
4.3 The lack of effects of 9R, 9S1R and 124R on melanoma B16 cells 
 It is surprising that 9R and 9S1R at 100µM, even at time points up to 96h, have no effect on the growth of 
melanoma B16 cells. The resistance mechanism(s) of B16 cells to PolyArgNulloPs are not known. It has been 
reported previously that CPPs other than R5 are more efficient at delivering lethal drugs in melanoma cell lines 
(Bowes melanoma cells [20], and SKMel-37 melanoma cells [15]). Changing the CPP in future studies of the 
NulloPs may yield better results. 
4.4 Comparison of the killing mechanisms of 9R and 9S1R 
The analysis of our results support the simple statement that peptides 9R and 9S1R have devastating effects 
on the mitochondria (as evidenced by their changes in cellular ATP, MMP, and ROS production), and 
consequently on cell growth. These effects are similar to the effects of amyloid beta peptide on nervous cells in 
Alzheimer disease, where the amyloid beta peptides are imported into mitochondria [22]. The CPP conjugated 
peptides do not cross the mitochondrial membrane [43], however the mitochondrial outer membrane has a 
porine protein which is permeable to compounds up to 5000 Da. Our PolyArgNulloPs are in the 1500 Da range, 
so it is possible that 9R accumulates in the mitochondria, a hypothesis that is under investigation in our lab. Our 
results, especially the contrast in effects of 9R and 9S1R on cellular ATP, suggest that 9S1R targets non-
mitochondrial cytosolic metabolism, whereas 9R attacks the mitochondria. 9S1R (50 µM) almost completely 
shuts down the ATP production in LnCap and MDA-MB-231 cells. We know that the respiratory chain in the 
mitochondria is the main source of ATP production in the cells, but glycolysis is important to cancer cell 
metabolism. The dramatic effect of 9S1R on ATP production (greater than sodium azide) may be caused by an 
inhibition of cellular glycolysis which automatically shuts down the respiratory chain in the mitochondria. 
Therefore, 9S1R is a candidate for the new metabolic strategy of treating cancer through glycolysis inhibition 
[54] and ATP depletion [28]. Peptide 9R also lowers cellular ATP content by attacking the mitochondria. 
4.5 Successful first use of the nullomer approach for drug development 
As with any in vitro drug screening, we realize that our results will need to be assessed in animal models. 
The treatment of cancer is based on the log-kill hypothesis established in 1970 by Skipper et al. [47]. Basically, 
this hypothesis states that at a certain dose, a cancer drug kills only a fraction of a tumor cell population. This 
leads to treatment cycles, in which every cycle enriches the proportion of resistant cells. So the results obtained 
in vitro for a single dose, may not match the results in vivo. Another difference between cell culture and animal 
studies is that in vitro we start with a small number of cells, and see if a cancer drug can inhibit the growth of 
that small population; but in vivo studies usually begin with established tumors. As the tumor grows in volume, 
the fraction of cycling cells diminishes; and as the log-kill hypothesis states, the response to cancer drugs 
declines. For this reason, cancer therapy uses a cocktail of drugs to attack multiple cellular targets. The 
relatively high doses used in this paper should not disqualify NulloPs as possible drugs for cancer treatment. 
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Cancer treatment is always a combination of drugs rather than a single drug, and our next phase of research is 
looking at possible combination drug treatments. The protocols based on the log-kill hypothesis have been 
improved recently by a new strategy focusing on the amount of drug per unit time, or dose intensity. This 
approach is based on high dose drug pulses rather than on a continuous regimen [19]. The first screening of 
potential anticancer drugs usually focuses a single drug treatment, and we have shown that our PolyArgNulloPs 
kill cancer cells by targeting mitochondrial health and ATP production. We do not envision their use as single 
anticancer drugs, but rather combined with other drugs. It is important to note that the difference in sensitivity 
was measured in rapidly growing, rather than quiescent cell cultures. We are currently studying the differential 
effects of NulloPs on cancer cells, versus dividing and quiescent normal cells.  
5. Conclusion 
We present here the first drug candidates produced by nullomer research. The bio-informatic approach 
which identified the NulloPs was based on the idea that rare or absent short sequences may be enriched for toxic 
or problematic peptides. We have shown that the differential effects of PolyArgNulloPs on cancer cells and 
normal cells indicate that these new peptides should be investigated and optimized for cancer treatment.  
 
 
 
 
 
 
 
Fig 1. Scanning electron microscopy of untreated and nullomer (124, 9R, 9S1) treated LnCap and MDA-MB-
231 cells.  
(A-H) lower magnification views. (a-h) higher magnification views. (A,a, B,b) Untreated control LnCap and 
MDA-MB-231 cells respectively. (C,c, D,d)  LnCap and MDA-MB-231 cells, respectively, treated with 
nullomer 124 (100 µM for 48 hr.). SEM examination of overall cell growth and membrane integrity after 
treatment with nullomer 124 are unchanged from untreated control cells. (E,e, F,f) LnCap and MDA-MB-231 
cells respectively treated with peptide 9R (100 µM for 48 hr.); overall cell growth markedly reduced compared 
with untreated control cell cultures. Cytopyknosis and membrane blebs appear (e, lower right and F,f). (G,g, 
H,h) LnCap and MDA-MB-231 cells, respectively, treated with peptide 9S1 (100 µM for 48 hr.); overall cell 
numbers less noticeably reduced than in cells treated with peptide 9R, but show widespread severe membrane 
damage consistent with necrosis. Scale bars = 50 µm (A-H), 25 µm (a-h). 
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Fig. 2. PolyArgNulloPs effects on cellular ATP level. Cells (3000/well) were seeded in 96 well plates (white 
plates from Nunc). After 24 h incubation, peptides 9R, 9S1R and 124R were added to the wells. Control 
conditions included untreated cells, and 100mM sodium azide. At 2h, 24h, and 48h a single reagent Cell Titer 
GlowTM (Promega,Madison) was added to the wells (v/v ratio with media), and ATP determined with emission 
reading using the SynergyMx plate reader. The statistical analysis was done with the GraphPadPRISM*.	  
Results are as mean ± SE (standard error) of three different experiments. NS, not significant. **∗p<0.05, 
∗∗p<0.01, ∗∗∗p<0.001 
(A), LnCap, at a 2h, b 24h, and c 48h. (B) MDA-MB-231 at a 2h, b 24h, and c 48h. 
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Fig. 3. PolyArgNulloPs effects on MMP.  LnCap cells (3000/well) were seeded in 96 well plates (white plates 
from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the wells. Control conditions 
included untreated cells, and H2O2 (0.01%) treated cells. At 24h, 50 µl of mitochondria staining solution (Mito 
Health) was added per well (following manufacturer’s protocol) and incubated for 30 mn. Relative fluorescence 
was measured in BioTek Synergy plate reader. The statistical analysis was done with the GraphPadPRISM*.	  
Results are as mean ± SE (standard error) of three different experiments. 
NS, not significant. *p<0.05, ***p<0.01, ***p<0.001 
(a), LnCap, at 24h. (b) MDA-MB-231, at 24h. 
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Fig. 4.  PolyArgNulloPs effects on ROS production. LnCap cells (3000/well) were seeded in 96 well plates 
(white plates from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the wells. Control 
conditions included untreated, and H2O2 (0.01%) treated cells. After 2h incubation, cells were treated with 
MitoSox red reagent for 10 mn, then washed with PBS, and the plate read in the microplate BioTek Synergy 
reader. The statistical analysis was done with the GraphPadPRISM*.	  Results are as mean ± SE (standard error) of 
three different experiments NS, not significant. *p<0.05, ***p<0.01, ***p<0.001 
(a), LnCap, at 2h. (b) MDA-MB-231, at 2h. 
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Fig. 5. Hemolytic activity of PolyArgNulloPs. RBCs collected from healthy donors were diluted 1:10 in PBS, 
and peptides 9R, 9S1R and 124R were added. Control conditions included PBS, and 1%Triton X-100. After 24h 
incubation at 37ºC with 100 rpm shaking, RBCs were centrifuged and the supernatant collected in a 96 well 
plates.  Absorbance was determined at 405 nm. The hemolytic activity in % was calculated using the formula: 
Hemolytic activity in %={[ASample-AControl]/[ATotal-AControl]}x100 
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Table 1. IC-50 (µM) Evolution. The IC-50 were calculated from the raw data of MTT readings at 570nm using 
the GraphPad PRISM* version 5.03. Dose response curves generated by non linear regression with GraphPad 
PRISM* were used to determine the IC-50s. Basically the x values from the y=f(x) function were transformed 
into Log10 scale. The y values normalized between 0% and 100% effects and IC-50 calculated. All results are 
expressed as mean ± SE (standard error). A p-value of less than 0.05 was considered statistically significant.  
>100* when there is no effects on cell growth for doses range used (10-100 µM). 
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Table 1: IC-50 (µM) Evolution 
 
Cell Line            Time (h)                                            Peptide 
 
                                                                             9R                      9S1R              124R 
 LnCap                         2h                              44±2.5           26±1.3              >100*                                
                                                             24h                              23±1.2           9±0.6              >100                              
                                                             48h                              28±1.6           8±0.5              >100 
MDA-MB-231            2h                              39±1.8           18±0.8               >100 
                         24h                              29±1.7           12±0.4               >100 
                         48h                              16±0.9           10±0.3                >100 
PCS                         24h                              28±1.1           26±1.2                >100 
                         48h                              35±1.3           22±0.9               88±2.3 
HMEC             24h                              20±0.8           17±0.8               29±1.1 
                         48h                              34±1.2           19±0.6               46±2.2 
HUT102             2h                              93±2.3           38±1.4                >100 
                         24h                              39±1.1           43±1.4                >100 
                         48h                              37±2.5           43±3.2                >100 
                         72h                              36±1.8           45±2.2                >100                                                                     
                         96h                              25±1.6           36±1.4                >100 
J774A.1             24h                              47±2.5           26±1.3               66±3.5 
                         96h                              12±0.7           17±1.2                 31±1.5 
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Suppl.R1.  Effect of PolyArgNulloPs on cell growth. 3000-5000 cells/well were seeded in 96-well plates. After 
24h incubation, peptides 9R, 9S1R and 124R were added to the wells. Control conditions included untreated, 
and H2O2 (0.01%) treated cells. Viability of cells was determined with an MTT assay at  different time points. 
(A) LnCap at a 2h, b 24h, and c 48h. (B) MDA-MB-231, at a 2h, b 24h, and c 48h. (C) B16, at a 2h, b 96h. (D) 
HUT 102, at a 2h, b 48h, c 72h and d 96h. (E) J774A.1, at a 2h, b 48h, c 72h and d 96h. (F) WI-38, at a 24h, b 
48h. (G) PCS, at a 24h, b 48h. (H) HMEC, at a 24h, b 48h.	  Results are as mean ± SE (standard error) of three 
different experiments. NS, not significant. *∗p<0.05, **∗∗p< 0.01,****∗∗∗p<0.001 
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(C) B16 
 
(D) HUT 102 
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(E) J774A.1 
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(G) PCS 
 
 
 
 
(H) HMEC 
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Suppl.R2. PolyArgNulloPs induced cell death (Live/Dead assay). LnCap cells (3000/well) were seeded in 96 
well plates (white plates from Nunc). After 24 h incubation peptides 9R, 9S1R and 124R were added to the 
wells. Control conditions included untreated, and H2O2 (0.01%) treated cells. After 2h incubation, Hoechst 
33342 and PI dyes were added to the cells, and fluorescent images were taken with a Zeiss axiovert 40 
microscope (Oberkochen, Germany) with SPOT imaging camera (Sterling Heights, MI). (A) LnCap. (B) MDA-
MB-231 
 (A) Ln Cap 
 
   
LnCap Untreated                          LnCap 124R 100 µM                     LnCap H202   0.01% 
   
LnCap 9R 10 µM                         LnCap 9R 50 µM                         LnCap 9R 100 µM 
 
   
LnCap 9S1R 10 µM                      LnCap 9S1R 50 µM                      LnCap 9S1R 100 µM 
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(B) MDA-MB-231 
   
MDA-MB-231 Untreated                 MDA-MB-231 124R 100 µM        MDA-MB-231 H202  0.01% 
   
MDA-MB-231 9R 10 µM               MDA-MB-231 9R 50 µM              MDA-MB-231   9R 100 µM   
   
MDA-MB-231 9S1R 10 µM          MDA-MB-231 9S1R 50 µM         MDA-MB-231   9S1R 100 µM   
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